- Home
- BTBD vs GNPX Comparison
BTBD vs GNPX Comparison
Compare BTBD & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- GNPX
- Stock Information
- Founded
- BTBD 1987
- GNPX 2009
- Country
- BTBD United States
- GNPX United States
- Employees
- BTBD N/A
- GNPX N/A
- Industry
- BTBD Restaurants
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- GNPX Health Care
- Exchange
- BTBD Nasdaq
- GNPX Nasdaq
- Market Cap
- BTBD 6.8M
- GNPX 6.2M
- IPO Year
- BTBD 2021
- GNPX 2018
- Fundamental
- Price
- BTBD $1.09
- GNPX $0.28
- Analyst Decision
- BTBD
- GNPX Strong Buy
- Analyst Count
- BTBD 0
- GNPX 1
- Target Price
- BTBD N/A
- GNPX $10.00
- AVG Volume (30 Days)
- BTBD 6.3K
- GNPX 7.4M
- Earning Date
- BTBD 05-14-2025
- GNPX 05-13-2025
- Dividend Yield
- BTBD N/A
- GNPX N/A
- EPS Growth
- BTBD N/A
- GNPX N/A
- EPS
- BTBD N/A
- GNPX N/A
- Revenue
- BTBD $14,823,472.00
- GNPX N/A
- Revenue This Year
- BTBD N/A
- GNPX N/A
- Revenue Next Year
- BTBD N/A
- GNPX N/A
- P/E Ratio
- BTBD N/A
- GNPX N/A
- Revenue Growth
- BTBD 5.30
- GNPX N/A
- 52 Week Low
- BTBD $1.06
- GNPX $0.22
- 52 Week High
- BTBD $2.02
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- BTBD 39.15
- GNPX 48.28
- Support Level
- BTBD $1.06
- GNPX $0.23
- Resistance Level
- BTBD $1.15
- GNPX $0.44
- Average True Range (ATR)
- BTBD 0.06
- GNPX 0.04
- MACD
- BTBD 0.01
- GNPX 0.01
- Stochastic Oscillator
- BTBD 13.64
- GNPX 58.91
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.